OVERACTIVE BLADDER SYNDROME: IS A REQUEST FOR A DOSE INCREASE INDICATIVE OF MORE SEVERE SYMPTOMS? RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, RISFNG-DOSE STUDY OF SOLIFENACIN (SUNRISE) Article Cardozo L., Avdoshin V., Wolski Z., Pavlik I., Sofras F.E., Toth Z., Vasco P.M., Drogendijk T., Wright D.M., Bolodeoku J. INTERNATIONAL UROGYNECOLOGY JOURNAL. SPRINGER LONDON LTD. Vol. 18. 2007.